SPOTLIGHT: Dara licenses Bayer drugs
DARA BioSciences in Raleigh, NC has licensed in IP and compounds for type 2 diabetes and dyslipidemia from Bayer HealthCare AG. Bayer gets an undisclosed upfront fee along with a schedule of milestones and royalties on any approved products. Bayer also retains certain commercialization rights. Release
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
